Teprotumumab
Teprotumumab confers long-term benefits in thyroid eye disease
Adults with active thyroid eye disease assigned the human monoclonal antibody teprotumumab experienced improvements in disease outcomes that persisted nearly 1 year after receiving the last trial dose, new study data show.
Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease
Most adults with thyroid eye disease who experienced meaningful improvement in proptosis after 21 weeks of teprotumumab treatment maintained proptosis response at week 72 without additional treatment, according to top-line data.
Smokers, women experience proptosis reduction with teprotumumab in thyroid eye disease
High-risk adults with active thyroid eye disease, such as smokers, women and older adults, experienced a reduction in outward bulging of the eye at 24 weeks that was similar to adults at lower risk for the disease, according to findings accepted for presentation at the Endocrine Society Annual Meeting.